Infliximab

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released May 26, 2009; last updated May 1, 2017; expires May 1, 2020

Historical note and terminology

Infliximab is a monoclonal antibody for the treatment of autoimmune diseases. Originally a mouse antibody, it was later developed into a human (humanized) antibody. Because it is a combination of mouse and human antibody, it is called a chimeric monoclonal antibody. The chimeric antibody was designed to reduce immunogenicity and improve pharmacokinetics in humans (Knight et al 1993). Infliximab has been approved by the United States Food and Drug Administration for the treatment of psoriasis, Crohn disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, sarcoidosis, and ulcerative colitis.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.